肿瘤(癌症)患者之家
首页
癌症知识
肿瘤中医药治疗
肿瘤药膳
肿瘤治疗技术
前沿资讯
临床试验招募
登录/注册
VIP特权
广告
广告加载中...

文章:

AP-1:肿瘤发生的双刃剑

AP-1: a double-edged sword in tumorigenesis

原文发布日期:2003-11-01

DOI: 10.1038/nrc1209

类型: Review Article

开放获取: 否

 

要点:

  1. AP-1 is a dimeric transcription factor that contains members from the JUN, FOS, ATF and MAF protein families.
  2. AP-1 activity can be regulated by dimer composition, transcription, post-translational modification and interactions with other proteins.
  3. Two of the components of AP-1 — c-JUN and c-FOS — were first identified as viral oncoproteins, so their role in tumorigenesis is well established.
  4. However, some JUN and FOS family proteins can suppress tumour formation. The decision as to whether AP-1 is oncogenic or anti-oncogenic depends on the cell type and its differentiation state, tumour stage and the genetic background of the tumour.
  5. AP-1 can exert its oncogenic or anti-oncogenic effects by regulating genes involved in cell proliferation, differentiation, apoptosis, angiogenesis and tumour invasion.
  6. AP-1 might be a good target for anticancer therapy.

 

要点翻译:

  1. AP-1是一种二聚体转录因子,其成员包含JUN、FOS、ATF和MAF蛋白家族。
  2. AP-1的活性可通过二聚体组成、转录、翻译后修饰以及与其他蛋白质的相互作用进行调控。
  3. AP-1的两个组分——c-JUN和c-FOS——最初被鉴定为病毒癌蛋白,因此它们在肿瘤发生中的作用已得到充分确认。
  4. 然而,部分JUN和FOS家族蛋白可抑制肿瘤形成。AP-1发挥促癌还是抑癌作用取决于细胞类型及其分化状态、肿瘤分期和肿瘤的遗传背景。
  5. AP-1可通过调控参与细胞增殖、分化、凋亡、血管生成和肿瘤侵袭的基因来发挥其促癌或抑癌效应。
  6. AP-1可能成为抗癌治疗的良好靶点。

 

英文摘要:

The AP-1 transcription factor is a dimeric complex that contains members of the JUN, FOS, ATF and MAF protein families. AP-1 proteins are primarily considered to be oncogenic, but recent studies have challenged this view — some AP-1 proteins, such as JUNB and c-FOS, have been shown to have tumour-suppressor activity. Here, we focus on the JUN and FOS proteins and aim to offer a new perspective on the molecular mechanisms that regulate the oncogenic and anti-oncogenic effects of AP-1 in tumour development.

摘要翻译: 

AP-1转录因子是一种包含JUN、FOS、ATF和MAF蛋白家族成员的二聚体复合物。AP-1蛋白传统上被视为致癌因子,但最新研究挑战了这一观点——某些AP-1蛋白(如JUNB和c-FOS)已被证实具有抑瘤活性。本文聚焦JUN与FOS蛋白,旨在从分子机制层面为AP-1在肿瘤发生中的双重致癌与抑癌效应提供新视角。

原文链接:

AP-1: a double-edged sword in tumorigenesis

广告
广告加载中...